Compare INTT & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | RVPH |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 10.0M |
| IPO Year | 1997 | N/A |
| Metric | INTT | RVPH |
|---|---|---|
| Price | $13.68 | $0.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $13.50 | ★ $66.67 |
| AVG Volume (30 Days) | 159.3K | ★ 1.7M |
| Earning Date | 05-01-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $5.24 | $0.17 |
| 52 Week High | $15.66 | $3.11 |
| Indicator | INTT | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 43.29 |
| Support Level | $7.21 | $0.32 |
| Resistance Level | $15.01 | $0.86 |
| Average True Range (ATR) | 0.89 | 0.20 |
| MACD | -0.27 | -0.16 |
| Stochastic Oscillator | 24.83 | 5.41 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.